Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Vail

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
BMC Veterinary Research|January 28, 2014
GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myelomaDouglas H Thamm, David M Vail, Ilene D Kurzman, et al.
Plos One|August 19, 2025
In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanomaAndrew T Kosharek, Cindy L Zuleger, William S Glass, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Preclinical study of dolastatin-10 in dogs with spontaneous neoplasiaDouglas H Thamm, E Gregory MacEwen, Brenda S Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Mike A Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Veterinary and Comparative Oncology|June 18, 2024
Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical TrialMarilia Takada, Keita Kitagawa, Yongzhen Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2004
The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposesLisa J Forrest, Thomas Rockwell Mackie, Ken Ruchala, et al.
Veterinary and Comparative Oncology|October 31, 2019
Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescenceElizabeth A Wood, Zhanping Lu, Shuai Jia, et al.
The Canadian Veterinary Journal = La Revue Veterinaire Canadienne|February 5, 2021
Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomyMarcus L Bradbury, Christine M Mullin, Shaban D Gillian, et al.
Journal of Veterinary Internal Medicine|February 18, 2020
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogsJacob R Cawley, Zachary M Wright, Karri Meleo, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
BMC Veterinary Research|January 28, 2014
GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myelomaDouglas H Thamm, David M Vail, Ilene D Kurzman, et al.
Plos One|August 19, 2025
In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanomaAndrew T Kosharek, Cindy L Zuleger, William S Glass, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2002
Preclinical study of dolastatin-10 in dogs with spontaneous neoplasiaDouglas H Thamm, E Gregory MacEwen, Brenda S Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Mike A Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Veterinary and Comparative Oncology|June 18, 2024
Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical TrialMarilia Takada, Keita Kitagawa, Yongzhen Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2004
The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposesLisa J Forrest, Thomas Rockwell Mackie, Ken Ruchala, et al.
Veterinary and Comparative Oncology|October 31, 2019
Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescenceElizabeth A Wood, Zhanping Lu, Shuai Jia, et al.
The Canadian Veterinary Journal = La Revue Veterinaire Canadienne|February 5, 2021
Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomyMarcus L Bradbury, Christine M Mullin, Shaban D Gillian, et al.
Journal of Veterinary Internal Medicine|February 18, 2020
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogsJacob R Cawley, Zachary M Wright, Karri Meleo, et al.
Pageof 8